Balanced Pharma

Balanced Pharma

Closed: Oct. 2023

About this raise

Balanced Pharma is raising funds on Dalmore Group through Reg A+ crowdfunding. The company intends to develop and sell a drug named Libracaine Dental. It is a pH-balanced injectable local anesthetic to be used for dental procedures. The drug is in the development phase and will be used to save time for dentists, reduce pain for patients, and improve the patient experience. J. Scott Keadle founded Balanced Pharma in 2020. The current crowdfunding campaign has no minimum target and a maximum target of $25,000,000. The campaign proceeds will be used for product development, product manufacturing, product marketing and disease awareness, intellectual property development, and general and administrative purposes.

Expand

Investment Overview

Invested this round: $572,572

Deal Terms

Total Commitments ($USD)

Platform
Dalmore Group
Start Date
04/11/2022
Close Date
Not Provided
Min. Goal
$100
Max Goal
$25,000,000
Min. Investment

$100

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$4.00

Pre-Money Valuation

$82,440,000

Company & Team

Company

Year Founded
2020
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
Medium
Capital Intensity
Low
Location
Cornelius, North Carolina
Business Type
Growth
Company Website
Visit Website

Team

Employees
4
Prior Founder Exits?
No
Founder Name
John Scott Keadle
Title
CEO

Financials

 Revenue
$0
 Monthly Burn
$75,082
 Runway
21.5 months

Balance Sheet

Cash and Cash Equivalents

$1,616,810

Investment Securities

$0

Total Assets

$1,696,346

Accounts Payable & Accrued Liabilities

$3,558

Long Term Debt

$0

Total Liabilities

$3,588

Total Stockholders' Equity

$1,692,758

Total Liabilities and Equity

$1,696,346

Statement of Comprehensive Income Information

Net Income

$-900,980

Earnings Per Share - Basic

$-0.05

Earnings Per Share - Diluted

$-0.05

Auditor: Artesian CPA, LLC
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$2,000,000
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
10/31/2023 Dalmore Group $82,440,000 $572,572 Equity - Common Funded RegA+
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Balanced Pharma on Dalmore Group 2022
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $82,440,000
Price per Share: $4.00

Follow company

Follow Balanced Pharma on Dalmore Group 2022

Buy Balanced Pharma's Deal Report

Warning: according to the close date for this deal, Balanced Pharma may no longer be accepting investments.

Balanced Pharma Deal Report

Get Kingscrowd's comprehensive report on Balanced Pharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Balanced Pharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Balanced Pharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge